VivaCell R&D programs are in continuous growth with the assessment of new molecules and new indications. To support the advancement of our candidates, VivaCell has assembled a proven management and scientific team with expertise in drug discovery, preclinical and clinical development.  

VivaCell vision is to be worldwide leaders in the development of new molecules acting on the PP2A/B55a/HIF pathway as well as the endocannabinoid system.

The current pipeline of the company is: